T10B9 monoclonal antibody: A short-acting nonstimulating monoclonal antibody that spares γδ T-cells and treats and prevents cellular rejection

Drug Design, Development and Therapy

Volumn , Issue 3, 2009, Pages 205-212

  Waid, Thomas H ^a   Thompson, John S ^a   Siemionow, Maria ^b   Brown, Stephen A ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Campath 1H, thymoglobulin; Monoclonal antibody; OKT3; T10B9.1A 31; T cell

Indexed keywords

ALEMTUZUMAB; CD3 ANTIGEN; CD69 ANTIGEN; CD71 ANTIGEN; CREATININE; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY T10B9; OKT 3; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ANTIGEN EXPRESSION; APOPTOSIS; CREATININE BLOOD LEVEL; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DNA FRAGMENTATION; DRUG DOSE ESCALATION; DRUG MANUFACTURE; DRUG MECHANISM; GAMMA DELTA T LYMPHOCYTE; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; INFECTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOCYTE DEPLETION; LYMPHOCYTE PROLIFERATION; MITOGENICITY; NONHUMAN; PANCREAS TRANSPLANTATION; PROPHYLAXIS; REVIEW; T LYMPHOCYTE;

EID: 77953658217     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/dddt.s2750     Document Type: Review

References (38)

1. Peleg AY, Husain S, Kwak EJ, et al. Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. Clin Infect Dis. 2007;44(2):204-212. (Pubitemid 46079982)
2. Alinari L, Lapalombella R, Andritsos L, Baiocchi RA, Lin TS, Byrd JC. Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia. Oncogene. 2007;26(25):3644-12653 (Pubitemid 46842714)
3. Chakrabarti S, Osman H, Collingham K, Milligan DW. Polyoma viruria following T-cell-depleted allogeneic transplants using Campath-1H: incidence and outcome in relation to graft manipulation, donor type and conditioning. Bone Marrow Transplant. 2003;31(5):379-386. (Pubitemid 36410684)
4. De Santo LS, Romano G, Mastroianni C, et al. Role of immunosuppressive regimen on the incidence and characteristics of cytomegalovirus infection in heart transplantation: a single-center experience with preemptive therapy. Transplant Proc. 2005;37(6):2684-2687. (Pubitemid 41354710)
5. Sepulveda L. Llancaqueo M, Zamorano J, Bermudez C, Cortes C. Cytomegalovirus infections in cardiac transplant patients: 5 and experience at a clinical hospital, university of Chile. Transplant Proc. 2007;39(3):622-624. (Pubitemid 46574812)
6. Nash RA, Dansey R, Storek J, et al. Epstein-Barr virus-associated posttransplantation lymphoproliferatvie disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. Biol Blood Marrow Transplant. 2003;9(9):583-591. (Pubitemid 38351790)
7. Lipshutz GS, Mahanty H, Feng S, et al. Polyomavirus-associated nephropathy in simultaneous kidney-pancreas transplant recipients: a single-center experience. Transplant Proc. 2004;36(4):1097-1098. (Pubitemid 38766288)
8. Duclos AJ, Krishnamurthi V, Lard M, et al. Prevalence and clinical course of BK virus nephropathy in pancreas after kidney transplant patients. Transplant Proc. 2006;38(10):3666-3672. (Pubitemid 44908420)
9. Casper J, Camitta B, Truitt R, et al. Unrelated bone marrow donor transplants for children with leukemia or myelodysplasia. Blood. 1995;85(9):2354-2363.
10. Bunin N, Aplenc R, Iannone R, et al. Unrelated donor bone marrow transplantation for children with severe aplastic anemia: minimal GVHD and durable engraftment with partial T cell depletion. Bone Marrow Transplant. 2005;35(4):369-373. (Pubitemid 40309482)
11. Thompson JS, Pomeroy C, Kryscio RJ, et al. Use of a T cell-specific monoclonal antibody, T10B9, in a novel allogeneic stem cell transplantation protocol for hematologic malignancy high-risk patients. Biol Blood Marrow Transplant. 2004;10(12):858-866. (Pubitemid 39625307)
12. Hensley-Downey PJ, Parrish RS, McDonald JS, et al. Combined in vitro and in vivo T lymphocyte depletion for the control of graft-versus-host diseases following haploidentical marrow transplant. Transplantation. 1996;61(5):735-745.
13. Fleming DR, Hensley-Downey PJ, Romond EH, et al. Allogeneic bone marrow transplantation with T-cell depleted partially matched related donors for advanced acute lymphoblastic leukemia in children and Adults: A comparative matched cohort study. Bone Marrow Transplant. 1996;17(6):917-922.
14. Waid TH, Lucas BA, Amlot P, et al. T10B9.1A-31 anti-T-cell monoclonal antibody: preclinical studies and clinical treatment of solid organ allograft rejection. Am J Kidney Dis. 1989;14(5 Suppl 2):61-70. (Pubitemid 20002190)
15. Brown SA, Lucas BA, Waid TH, McKeown JW, Barve S, Jackson LR, Thompson JS. T10B9 (MEDI-500) mediated immunosuppression: studies on the mechanism of action. Clin Transplant. 1996;10(6 part 2):607-613. (Pubitemid 27010909)
16. Waid TH, Lucas BA, Thompson JS, et al. Treatment of acute cellular rejection with T10B9.1A-31 or OKT3 in renal allograft recipients. Transplantation. 1992;53(1):80-86.
17. Waid TH, Lucas BA, Thompson JS, et al. Treatment of acute cellular kidney allograft rejection with T10B9.1A-31 anti-T-cell monoclonal antibody. Transplant Proc. 1989;21(1 PT 2):1778-1784.
18. Waid TH, Lucas BA, Thompson JS, et al. Treatment of renal allograft rejection with T10B9.1A-31 or OKT3: Final analysis of a phase 2 clinical trial. Transplantation. 1997;64(2):274-281.
19. Waid TH, Thompson JS, McKeown JW, Brown SA, Sekela ME. Induction immunotherapy in heart transplantation with T10B9.1A-31: A phase 1 study. J Heart Lung Transplant. 1997:16(9):913-916.
20. Reddy KS, Ranjan D, Johnston TD, et al. Pancreas transplantation, current status and experience at the University of Kentucky. J Ky Medication Assn. 2002;100:278-284.
21. Thedrez A, Sabourin C, Gertner J, et al. Self/non-self discrimination by human gamma/delta T-cells: simple solutions for a complex issue question. Immunological Rev. 2007;215:123-135. (Pubitemid 46212235)
22. Jameson J, Havran WL. Skin gamma/delta T-cell functions in homeostasis and wound healing. Immunological Rev. 2007;215:114-122. (Pubitemid 46212234)
23. Lamb LS, Lopez RV. γδ T-Cells: A New Frontier for Immunotherapy? Biol Blood Marrow Transplant. 2005;11:161-168.
24. D'Offizi G, Giola C, Martini F, et al. Gamma/delta T-cells and resolution of cytomegalovirus infection in HIV/HCV co-infected patients after liver transplantation. Transplantation. 2005;80:1523-1524. (Pubitemid 41803639)
25. Ponomarev ED, Dittel BN. Gamma/delta T-cells regulate the extent and duration of inflammation in the central nervous system by a Fas ligand-dependent mechanism. J Immunol. 2005;174:4678-4687. (Pubitemid 40504550)
26. Poccia F, Agrati C, Castilletti C, et al. Anti-severe acute respiratory syndrome coronavirus immune responses: the role played by V gamma 9V delta 2 T cells. J Infect Dis. 2006;193:1244-1249.
27. Agrati C, Castilletti C, Santis R, et al. Interferon-gamma-mediated antiviral immunity against orthopoxvirus is provided by gamma/delta T-cells. J Infect Dis. 2006;193:1606-1607. (Pubitemid 43794591)
28. Wang T, Gao Y, Scully E, et al. Gamma delta T cells facilitate adaptive immunity against West Nile virus infection in mice. J Immunol. 2006;177(3):1825-1832. (Pubitemid 44092520)
29. Lockard E, Green AM, Flynn JL. IL-17 production is dominated by gammadelta T-cells rather than CD4 T-cells during Mycobacterium tuberculosis infection. J Immunol. 2006;177:4662-4669.
30. Van-der-Heyde HC, Batcheider JM, Sandor M, Weidanz WP. Splenic gammadelta T-cells regulated by CD4+ T-cells are required to control chronic plasmodium chabaudi malaria in the V-cell-deficient mouse. IMF Immun. 2006;74:2717-12715 (Pubitemid 43672980)
31. Manno N, Shiohara T, Yamamoto TH, et al. Gamma/delta δδ T-cells; firefighters or fire boosters in the front lines of inflammatory responses. Immunological Rev. 2007;215:103-113. (Pubitemid 46212233)
32. Koshiba T, Li Y, Takemura M, et al. Clinical, immunological, and pathological aspects of operational tolerance after pediatric living-donor liver transplantation. Transplant Immunol. 2007;17:94-97. (Pubitemid 46240888)
33. Vodanovic-Jankovic S, Vrobyski WR. Gamma/delta T-cells do not require fully functional cytotoxic pathways or the ability to recognize recipient alloantigens to prevent graft rejection. Biol Blood Marrow Transplant. 2006;12:1125-1134. (Pubitemid 44660864)
34. Godder KT, Henslee-Downey PJ, Mehta J, et al. Long term disease-free survival in acute leukemia patients recovering with increased γδ T-cells after partially mismatched related donor bone marrow transplantation." Bone Marrow Transplantation. 2007;39:751-757. (Pubitemid 46901973)
35. Brennan D, et al. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med. 2006;355(19):1967-1977. (Pubitemid 44708016)
36. Scharpf J, Strome M, Siemionow M. Immunomodulation with anti-alphabeta T-cell receptor monoclonal antibodies in combination with cyclosporine A improves regeneration in nerve allografts. Microsurgery. 2006;26:599-607. (Pubitemid 44904411)
37. Nomoto K, Yung-Yu K, Omoto K, et al. Tolerance induction in a fully allogeneic combination using anti-T cell receptor-αβ monoclonal antibody, low dose irradiation, and donor bone marrow transfusion. Transplantation. 1995;59:395-401.
38. Ozer K, Oke R, Gurunluoglu R. Induction of tolerance to hind limb allografts in rats receiving cyclosporine A and antilymphocyte serum: effect of duration of the treatment. Transplantation 2003;75:31-36. (Pubitemid 36139691)